China-based Ascletis Pharma Inc. (HKG: 1672) has announced a supplementary agreement with Swiss pharmaceutical giant Roche, terminating the promotion services previously provided by Ascletis for Roche’s Pegasys (peginterferon alfa-2a) as of December 31, 2022. The initial partnership, established in November 2018, granted Ascletis exclusive marketing and promotion rights to the hepatitis therapy in mainland China.
Drug Background and Market Adjustments
Pegasys, used to treat hepatitis B and C viruses, was first approved in the US and Europe in 2002 and subsequently gained market approval in China in 2003. Roche has decided to cease promotion of the drug in mainland China, citing market strategy adjustments in the region.
Future Outlook
The termination of promotion services for Pegasys marks a strategic shift for both Ascletis Pharma and Roche. As Ascletis focuses on its core competencies and pipeline development, Roche continues to adapt its market strategies to align with evolving healthcare landscapes. This move underscores the dynamic nature of the pharmaceutical industry, where companies must continually reassess and optimize their market positions.-Fineline Info & Tech
